Join CMS for a Stakeholder Call on the Medicare Coverage Policy for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease

Join CMS for a Stakeholder Call on the Medicare Coverage Policy for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease   On April 7, 2022, the Centers for Medicare & Medicaid Services (CMS) released a national policy for coverage of aducanumab (brand name Aduhelm™) and any future monoclonal antibodies directed against amyloid approved by the FDA with an indication for use in treating Alzheimer's disease. From the onset, CMS ran a transparent, evidence-based process that incorporated more than 10,000 stakeholder comments and more than 250 peer-reviewed documents into the determination.  As a part of CMS' continued commitment to engage stakeholders on an ongoing basis, CMS will hold a national stakeholder call on May 11, 2022 to review the recent finalized coverage decision on monoclonal antibodies directed against amyloid for the treatment of Alzheimer's Disease. CMS will review the overall coverage process, the finalized decision, and address questions as time allows.     When: Wednesday, May 11, 2022, 11:00 AM ET   Who should attend: This stakeholder call is intended for anyone in the healthcare industry, but specifically for healthcare issuers, providers of healthcare, and healthcare advocates.   RSVP: https://cms.zoomgov.com/webinar/register/WN_WPnryrzfS_eQnwp6Fnndag   After registering, you will receive a confirmation email containing information about joining the webinar.   This meeting is closed to press.    Additional Resources:  For the complete press release visit: https://www.cms.gov/newsroom/press-releases/cms-finalizes-medicare-coverage-policy-monoclonal-antibodies-directed-against-amyloid-treatment For a fact sheet on Medicare coverage policy for monoclonal antibodies directed against amyloid for the treatment of Alzheimer's disease, visit: https://www.cms.gov/newsroom/fact-sheets/medicare-coverage-policy-monoclonal-antibodies-directed-against-amyloid-treatment-alzheimers-disease.  To read the final NCD CED decision memorandum, visit: https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=N&ncaid=305  Centers for Medicare & Medicaid Services (CMS) has sent this update. To contact Centers for Medicare & Medicaid Services (CMS) go to our contact us page. You're getting this message because you subscribed to get email updates from the Centers for Medicare & Medicaid Services (CMS). Update your subscriptions, modify your password or email address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your email address to log in. If you have questions or problems with the subscription service, please contact subscriberhelp.govdelivery.com. This service is provided to you at no charge by Centers for Medicare & Medicaid Services (CMS). This email was sent to rssproject471@gmail.com using GovDelivery Communications Cloud 7500 Security Boulevard · Baltimore MD 21244

Tweet

Postingan terkait:

— Monday, May 9, 2022 — Add Comment